Hematology Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4000
Buy Report Download FREE Resources

Published: May 25, 2023 Report Code: GDME1551EPD-ST

Select Item

Hematology Pipeline Market Report Overview

Hematology tests evaluate numerous conditions involving blood and its components and the tests that generate results immediately and can be done in a limited resource setting. The hematology pipeline market research report provides comprehensive information about the hematology pipeline reconstruction with a comparative analysis of the reconstruction at various stages of development and information about the clinical trials which are in progress.

Key Segments ·       Immunohematology

·       Hematology Reagents

·       Hemostasis Calibrators and Controls

·       Hematology Analyzer Reagents

·       Haematology Calibrators and Controls

·       ABO Typing, Antibody Detection

·       Differential Counters

·       Hematology Cell Counters

·       Hemoglobinometers
Key Territories ·       The US

·       Israel

·       Europe

·       India

·       Australia

·       Canada
Key Regulatory Paths ·       510(k)

·       CE

·       CE-IVD

·       TGA

·       PMA

·       MDL

·       ICAC
Leading Companies ·       AbSorber AB

·       Aggredyne Inc

·       Alba Bioscience Limited

·       Amity University

·       Analyticon Biotechnologies AG

·       Biofortuna Ltd
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Hematology Pipeline Market Segments

Some of the key segments in the hematology pipeline market are immunohematology, hematology reagents, hemostasis calibrators and controls, hematology analyzer reagents, hematology calibrators and controls, abo typing, antibody detection, differential counters, hematology cell counters, and hemoglobinometers among others. As of May 2023, immunohematology has the highest share.

Hematology Pipeline Market Analysis, by Segments, 2023 (%)

Hematology Pipeline Market Analysis, by Segments, 2023 (%)

For more segment insights into the hematology pipeline market, download a free report sample

Hematology Pipeline Market Segmentation by Territories

Some of the key territories having hematology products in the pipeline are the US, Israel, Europe, India, Australia, and Canada. As of May 2023, the US had the highest number of products in the pipeline compared to the others.

Hematology Pipeline Market Analysis, by Territories, 2023 (%)

Hematology Pipeline Market Analysis, by Territories, 2023 (%)

For more territory insights into the hematology pipeline market, download a free report sample

Hematology Pipeline Market Segmentation by Regulatory Paths

Some of the key regulatory paths followed by the hematology pipeline products are 510(k), CE, CE-IVD, TGA, PMA, MDL, and ICAC among others.  As of May 2023, most of the reconstruction follows the 510(k) pathway to enter the market.

Hematology Pipeline Market Analysis, by Regulatory Paths, 2023 (%)

Hematology Pipeline Market Analysis, by Regulatory Paths, 2023 (%)

For more regulatory path insights into the hematology pipeline market, download a free report sample

Hematology Pipeline Market – Competitive Landscape

Some of the leading companies in the hematology pipeline reconstruction market are AbSorber AB, Aggredyne Inc, Alba Bioscience Limited, Amity University, Analyticon Biotechnologies AG, and Biofortuna Ltd among others.

Aggredyne Inc Company Overview: Aggredyne Inc (Aggredyne) is a medical device company. It provides light scattering aggregometry devices. The company offers products that include laser-light scattering platelet aggregometer and aggre guide systems. It’s laser-light scattering Platelet aggregometers provide analyzing and measuring patients’ platelet function and stickiness. The company’s agree guide systems are automated multi-channel instruments that provide testing of the entire platelet drug panel with only one sample of whole blood. It distributes its products through a network of distributors in Saudi Arabia, Israel, Switzerland, Turkey, Belgium, Taiwan, India, Korea, the UAE, Qatar, Algeria, Jordan, Bahrain, Sudan, and others. Aggredyne is headquartered in Houston, Texas, the US.

Segments Covered in the Report

Hematology Pipeline Market Segments Outlook

  • Immunohematology
  • Hematology Reagents
  • Hemostasis Calibrators and Controls
  • Hematology Analyzer Reagents
  • Haematology Calibrators and Controls
  • ABO Typing, Antibody Detection
  • Differential Counters
  • Hematology Cell Counters
  • Hemoglobinometers

Hematology Pipeline Market Territories Outlook

  • The US
  • Israel
  • Europe
  • India
  • Australia
  • Canada

Hematology Pipeline Market Regulatory Paths Outlook

  • 510(k)
  • CE
  • CE-IVD
  • TGA
  • PMA
  • MDL
  • ICAC

Scope

  • Extensive coverage of the hematology under development

  • Reviews details of major pipeline reconstruction which include, product description, licensing and collaboration details, and other developmental activities

  • Reviews the major players involved in the development of hematology and list all their pipeline projects

  • The coverage of pipeline reconstruction based on various stages of development ranging from Early Development to Approved / Issued stage

  • The report provides key clinical trial data of ongoing trials specific to pipeline reconstruction

  • Recent developments in the segment/industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies

  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage

  • Identify and understand important and diverse types of hematology under development

  • Develop market-entry and market-expansion strategies

  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

  • In-depth analysis of the product’s current stage of development, territory, and estimated launch date

AbSorber AB
Aggredyne Inc
Alba Bioscience Limited
Amity University
Analyticon Biotechnologies AG
Biofortuna Ltd
Blaze Medical Devices, LLC
Calviri Inc
Cellphire Inc
Children's Hospital of Philadelphia
CPSI Biotech
CW Optics Inc
Diagnostica Stago Inc
DNA Medicine Institute (DMI) Inc
ELITechGroup Inc
Embryyo Technologies Pvt Ltd
Endpoint Health Inc
Genome Diagnostics B.V.
Grifols SA
Haemokinesis Pty Ltd
Haemonetics Corp
In Vitro Diagnostic Solutions Inc
Indian Institute of Technology Bombay
Instrumentation Laboratory Co
King's College London
Laboratorios Alpha San Ignacio Pharma S.L.
LeukoLab
Massachusetts General Hospital
Medical University of Vienna
MedPrime Technologies Pvt. Ltd.
Mylab Discovery Solutions Pvt Ltd
Nanospot.ai Inc
Neuron Biopharma SA
Northwestern University
Ortho Clinical Diagnostics Holdings Plc
PixCell Medical Technologies Ltd
Plakdx LLC
Pro Test Diagnostics AB
Quotient Ltd
Rapidx, Ltd.
Redbud Labs Inc
Sebia SA
SiDx Inc
Sigma Bio-Instrument Inc
Stichting Lygature
Streck Inc
TBG Diagnostics Ltd
The University of British Columbia
Transfusion & Transplantation Technologies (Inactive)
University of California Los Angeles
University of Utah
Victory Square Health Inc
Washington University in St Louis

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 9

|1.2 List of Figures 15

2 Introduction 16

2.1 Hematology Overview 16

3 Products under Development 17

3.1 Hematology – Pipeline Products by Stage of Development 17

3.2 Hematology – Pipeline Products by Segment 18

3.3 Hematology – Pipeline Products by Territory 19

3.4 Hematology – Pipeline Products by Regulatory Path 20

3.5 Hematology – Pipeline Products by Estimated Approval Date 21

3.6 Hematology – Ongoing Clinical Trials 22

4 Hematology – Pipeline Products under Development by Companies 23

4.1 Hematology Companies – Pipeline Products by Stage of Development 23

4.2 Hematology – Pipeline Products by Stage of Development 26

5 Hematology Companies and Product Overview 29

5.1 AbSorber AB Company Overview 29

5.1.1 AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 29

5.2 Aggredyne Inc Company Overview 30

5.2.1 Aggredyne Inc Pipeline Products & Ongoing Clinical Trials Overview 30

5.3 Alba Bioscience Limited Company Overview 31

5.3.1 Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 31

5.4 Amity University Company Overview 34

5.4.1 Amity University Pipeline Products & Ongoing Clinical Trials Overview 34

5.5 Analyticon Biotechnologies AG Company Overview 35

5.5.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 35

5.6 Biofortuna Ltd Company Overview 37

5.6.1 Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 37

5.7 Blaze Medical Devices, LLC Company Overview 44

5.7.1 Blaze Medical Devices, LLC Pipeline Products & Ongoing Clinical Trials Overview 44

5.8 Calviri Inc Company Overview 45

5.8.1 Calviri Inc Pipeline Products & Ongoing Clinical Trials Overview 45

5.9 Cellphire Inc Company Overview 46

5.9.1 Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 46

5.10 Children’s Hospital of Philadelphia Company Overview 47

5.10.1 Children’s Hospital of Philadelphia Pipeline Products & Ongoing Clinical Trials Overview 47

5.11 CPSI Biotech Company Overview 48

5.11.1 CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 48

5.12 CW Optics Inc Company Overview 49

5.12.1 CW Optics Inc Pipeline Products & Ongoing Clinical Trials Overview 49

5.13 Diagnostica Stago Inc Company Overview 50

5.13.1 Diagnostica Stago Inc Pipeline Products & Ongoing Clinical Trials Overview 50

5.14 DNA Medicine Institute (DMI) Inc Company Overview 56

5.14.1 DNA Medicine Institute (DMI) Inc Pipeline Products & Ongoing Clinical Trials Overview 56

5.15 ELITechGroup Inc Company Overview 57

5.15.1 ELITechGroup Inc Pipeline Products & Ongoing Clinical Trials Overview 57

5.16 Embryyo Technologies Pvt Ltd Company Overview 58

5.16.1 Embryyo Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 58

5.17 Endpoint Health Inc Company Overview 60

5.17.1 Endpoint Health Inc Pipeline Products & Ongoing Clinical Trials Overview 60

5.18 Genome Diagnostics B.V. Company Overview 61

5.18.1 Genome Diagnostics B.V. Pipeline Products & Ongoing Clinical Trials Overview 61

5.19 Grifols SA Company Overview 63

5.19.1 Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 63

5.20 Haemokinesis Pty Ltd Company Overview 65

5.20.1 Haemokinesis Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 65

5.21 Haemonetics Corp Company Overview 66

5.21.1 Haemonetics Corp Pipeline Products & Ongoing Clinical Trials Overview 66

5.22 In Vitro Diagnostic Solutions Inc Company Overview 67

5.22.1 In Vitro Diagnostic Solutions Inc Pipeline Products & Ongoing Clinical Trials Overview 67

5.23 Indian Institute of Technology Bombay Company Overview 68

5.23.1 Indian Institute of Technology Bombay Pipeline Products & Ongoing Clinical Trials Overview 68

5.24 Instrumentation Laboratory Co Company Overview 69

5.24.1 Instrumentation Laboratory Co Pipeline Products & Ongoing Clinical Trials Overview 69

5.25 King’s College London Company Overview 70

5.25.1 King’s College London Pipeline Products & Ongoing Clinical Trials Overview 70

5.26 Laboratorios Alpha San Ignacio Pharma S.L. Company Overview 71

5.26.1 Laboratorios Alpha San Ignacio Pharma S.L. Pipeline Products & Ongoing Clinical Trials Overview 71

5.27 LeukoLab Company Overview 72

5.27.1 LeukoLab Pipeline Products & Ongoing Clinical Trials Overview 72

5.28 Massachusetts General Hospital Company Overview 75

5.28.1 Massachusetts General Hospital Pipeline Products & Ongoing Clinical Trials Overview 75

5.29 Medical University of Vienna Company Overview 76

5.29.1 Medical University of Vienna Pipeline Products & Ongoing Clinical Trials Overview 76

5.30 MedPrime Technologies Pvt. Ltd. Company Overview 77

5.30.1 MedPrime Technologies Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 77

5.31 Mylab Discovery Solutions Pvt Ltd Company Overview 78

5.31.1 Mylab Discovery Solutions Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 78

5.32 Nanospot.ai Inc Company Overview 79

5.32.1 Nanospot.ai Inc Pipeline Products & Ongoing Clinical Trials Overview 79

5.33 Neuron Biopharma SA Company Overview 80

5.33.1 Neuron Biopharma SA Pipeline Products & Ongoing Clinical Trials Overview 80

5.34 Northwestern University Company Overview 81

5.34.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 81

5.35 Ortho Clinical Diagnostics Holdings Plc Company Overview 82

5.35.1 Ortho Clinical Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 82

5.36 PixCell Medical Technologies Ltd Company Overview 84

5.36.1 PixCell Medical Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 84

5.37 Plakdx LLC Company Overview 86

5.37.1 Plakdx LLC Pipeline Products & Ongoing Clinical Trials Overview 86

5.38 Pro Test Diagnostics AB Company Overview 87

5.38.1 Pro Test Diagnostics AB Pipeline Products & Ongoing Clinical Trials Overview 87

5.39 Quotient Ltd Company Overview 88

5.39.1 Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 88

5.40 Rapidx, Ltd. Company Overview 95

5.40.1 Rapidx, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 95

5.41 Redbud Labs Inc Company Overview 96

5.41.1 Redbud Labs Inc Pipeline Products & Ongoing Clinical Trials Overview 96

5.42 Sebia SA Company Overview 97

5.42.1 Sebia SA Pipeline Products & Ongoing Clinical Trials Overview 97

5.43 SiDx Inc Company Overview 101

5.43.1 SiDx Inc Pipeline Products & Ongoing Clinical Trials Overview 101

5.44 Sigma Bio-Instrument Inc Company Overview 102

5.44.1 Sigma Bio-Instrument Inc Pipeline Products & Ongoing Clinical Trials Overview 102

5.45 Stichting Lygature Company Overview 103

5.45.1 Stichting Lygature Pipeline Products & Ongoing Clinical Trials Overview 103

5.46 Streck Inc Company Overview 104

5.46.1 Streck Inc Pipeline Products & Ongoing Clinical Trials Overview 104

5.47 TBG Diagnostics Ltd Company Overview 108

5.47.1 TBG Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 108

5.48 The University of British Columbia Company Overview 109

5.48.1 The University of British Columbia Pipeline Products & Ongoing Clinical Trials Overview 109

5.49 Transfusion & Transplantation Technologies (Inactive) Company Overview 110

5.49.1 Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 110

5.50 University of California Los Angeles Company Overview 117

5.50.1 University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 117

5.51 University of Utah Company Overview 118

5.51.1 University of Utah Pipeline Products & Ongoing Clinical Trials Overview 118

5.52 Victory Square Health Inc Company Overview 119

5.52.1 Victory Square Health Inc Pipeline Products & Ongoing Clinical Trials Overview 119

5.53 Washington University in St Louis Company Overview 120

5.53.1 Washington University in St Louis Pipeline Products & Ongoing Clinical Trials Overview 120

6 Hematology- Recent Developments 121

6.1 May 17, 2023: Abcam: Statement on potential extraordinary general meeting 121

6.2 May 17, 2023: Nihon Kohden announces consolidated financial results for the fiscal year ended March 31, 2023 121

6.3 May 15, 2023: Terumo announces consolidated financial results for the fiscal year ended March 31, 2023 121

6.4 May 12, 2023: Horiba announces summary of consolidated financial statements for the three months ended March 31, 2023 121

6.5 May 11, 2023: Haemonetics announces fourth quarter fiscal year 2023 earnings 121

6.6 May 11, 2023: Medtronic to announce financial results for its fourth quarter and full fiscal year 2023 122

6.7 May 11, 2023: Accelerate Diagnostics reports first quarter 2023 financial results 122

6.8 May 09, 2023: Grifols delivers strong first quarter financials with 23% revenue growth and an adjusted EBITDA margin above guidance of 21% 124

6.9 May 09, 2023: Redsense Medical announces interim report Q1 January – March, 2023 125

6.10 May 09, 2023: HCW Biologics reports first quarter 2023 financial results and recent business highlights 127

6.11 May 05, 2023: CellaVision: Bulletin from annual general meeting 2023 128

6.12 May 04, 2023: Kimball Electronics announces results for Q3 ended March 31, 2023 129

6.13 Apr 25, 2023: Haemonetics sets date for publishing fourth quarter and fiscal year 2023 results: May 11, 2023 130

6.14 Apr 21, 2023: Invitation to presentation of the CellaVision report for the first quarter 2023 on May 4, at 11:00 CEST 130

6.15 Apr 12, 2023: Medtronic has a layoff in California 130

6.16 Apr 06, 2023: Integrated Diagnostics Holdings Announces Final Results 130

6.17 Apr 06, 2023: Integrated Diagnostics Holdings concludes 2022 reporting solid 18% growth in non-Covid revenues 132

6.18 Apr 05, 2023: Hemcheck has received a first order from the university hospital Charité in Berlin 135

6.19 Apr 03, 2023: Cellavision Notice Of Annual General Meeting 135

6.20 Apr 03, 2023: Angle Notice of Preliminary Results and Webcast 142

6.21 Mar 30, 2023: Abcam Publication of 2022 Annual Report and Accounts and Notice of Annual General Meeting 142

6.22 Mar 30, 2023: Abcam Publication of 2022 Annual Report and Accounts and Notice of Annual General Meeting 142

6.23 Mar 28, 2023: EKF Diagnostics Holdings Announces its final results for the year ended 31 December 2022 142

6.24 Mar 16, 2023: Medtronic joins in $25M funding round for home monitoring company 144

6.25 Mar 15, 2023: Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results 144

6.26 Mar 14, 2023: Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement 144

6.27 Mar 08, 2023: Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors 145

6.28 Mar 03, 2023: Grifols Announces Full Year 2022 Earnings 145

6.29 Feb 22, 2023: Thomas Glanzmann new Grifols Executive Chairman, after Steven F. Mayer resignation 145

6.30 Feb 22, 2023: Novo Nordisk Notice for the Annual General Meeting 146

6.31 Feb 16, 2023: Labcorp Announces 2022 Fourth Quarter and Full-Year Results 147

6.32 Feb 14, 2023: Horiba Announces Summary of Consolidated Financial Statements for the Year Ended December 31, 2022 149

6.33 Feb 14, 2023: Hemcheck has received an additional follow up order from its UK distributor 150

6.34 Feb 09, 2023: Sysmex Announces Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2023 150

6.35 Feb 09, 2023: Terumo Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023 153

6.36 Feb 09, 2023: Terumo Corp Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2022 153

6.37 Feb 08, 2023: Sysmex Corp. Notice of Changes in Representative Directors 154

6.38 Feb 08, 2023: Nihon Kohden Announces Consolidated Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2023 154

6.39 Feb 07, 2023: Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2023 Results; Updates Fiscal 2023 Guidance 154

6.40 Feb 06, 2023: Kimball Electronics announces results for Q2 ended December 31, 2022 156

6.41 Feb 02, 2023: F. Hoffmann-La Roche Announces Financial Results for fiscal 2022 156

6.42 Feb 01, 2023: Novartis Announces Annual Report 2022 157

6.43 Feb 01, 2023: SDI Group Announces Board Appointment 158

6.44 Jan 30, 2023: Shionogi & Co Announces 3rd Quarter of Fiscal 2022 Financial Results 158

6.45 Jan 24, 2023: CellaVision’s Invitation for presentation of the report for the fourth quarter 2022 on February 7, at 11:00 CET 158

6.46 Jan 16, 2023: TheraDiag Reports 2022 Revenue of €12.2 Million, up

9.7% 159

6.47 Jan 16, 2023: Hemcheck has received another follow up order from its Irish distributor 160

6.48 Jan 10, 2023: Kimball Electronics reports retirement of chairman and CEO 160

6.49 Jan 06, 2023: Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023 161

6.50 Jan 06, 2023: BD Announces Webcast of Annual Meeting of Shareholders 162

6.51 Jan 06, 2023: Abbott, Blood Centers of America launch first-of-its-kind mixed reality experience for use during blood donation 162

6.52 Jan 05, 2023: Angle : Announces business update 163

6.53 Dec 20, 2022: Hemcheck has received a follow up order from its Irish distributor 165

6.54 Dec 19, 2022: Vaxart Names Phillip Lee as Chief Financial Officer 166

6.55 Dec 13, 2022: Thomas Schinecker replaces Severin Schwan as Roche’s new CEO 166

6.56 Dec 08, 2022: BD Releases 2022 Global Inclusion, Diversity and Equity Annual Report 166

6.57 Dec 07, 2022: HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform 167

6.58 Dec 07, 2022: Hemcheck has received an important follow up order from Deutsches Herzzentrum Berlin 168

6.59 Nov 25, 2022: Shionogi opens new European headquarters in Amsterdam 168

6.60 Nov 23, 2022: Medtronic Reports Quarterly Earnings 168

6.61 Nov 22, 2022: Medtronic reports second quarter fiscal 2023 financial results 168

6.62 Nov 22, 2022: Hemcheck receives follow up order from its Italian distributor 174

6.63 Nov 17, 2022: Integrated Diagnostics Holdings 3rd Quarter Results 174

6.64 Nov 15, 2022: Medtronic Set to Announce Earnings on Tuesday 177

6.65 Nov 14, 2022: ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights 177

6.66 Nov 14, 2022: Accelerate Diagnostics Reports Third Quarter 2022 Financial Results 178

6.67 Nov 14, 2022: OncoNano Medicine Announces New Preclinical Data for ON-BOARD Platform for Delivery of Bispecific T Cell Engagers and a Therapeutic Cytokine at the Society for Immunotherapy of Cancer Annual Meeting 179

6.68 Nov 11, 2022: Distribution agreement signed for the Italian market 180

6.69 Nov 11, 2022: Horiba Announces Summary of Consolidated Financial Statements for the Nine Months Ended September 30, 2022 181

6.70 Nov 11, 2022: Distribution agreement signed for the Italian market 181

6.71 Nov 10, 2022: Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update 181

6.72 Nov 10, 2022: Terumo Corp Announces Consolidated Financial Results for the Second Quarter Ended September 30, 2022 183

6.73 Nov 09, 2022: Redsense Medical Interim Report Q3 – July – September, 2022 183

6.74 Nov 09, 2022: Redsense Medical Announces Interim Report Q3 – July – September, 2022 186

6.75 Nov 09, 2022: Nihon Kohden Consolidated Financial Results for the 2nd Quarter of the Fiscal Year Ending March 31, 2023 186

6.76 Nov 08, 2022: Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results 187

6.77 Nov 08, 2022: Quanterix Corp. Releases Operating Results for Third Quarter 2022 189

6.78 Nov 07, 2022: HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights 190

6.79 Nov 03, 2022: Trinity Biotech Announces Quarter 2 2022 Financial Results And Preliminary Q3 2022 Revenue Guidance 192

6.80 Nov 01, 2022: Aspira Women’s Health to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10 196

6.81 Oct 31, 2022: Shionogi announces 1st Half of Fiscal 2022 Financial Results 196

6.82 Oct 31, 2022: IDH and its Jordanian subsidiary, Biolab, to Launch Greenfield Diagnostic Venture in Saudi Arabia in Partnership with Izhoor Medical, a company owned by Fawaz Alhokair 197

6.83 Oct 27, 2022: Bio-Rad Reports Third-Quarter 2022 Financial Results 199

6.84 Oct 26, 2022: CellaVision announces Nomination Committee for the Annual General Meeting 2023 200

6.85 Oct 19, 2022: Nihon Kohden Announces a Revision to its Forecast for Financial Results 201

6.86 Oct 17, 2022: Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022 201

6.87 Oct 13, 2022: Novartis to lay off 400 at Dublin campus amid global restructuring 201

6.88 Oct 13, 2022: Novartis to cut its Irish workforce by up to 25% 201

6.89 Oct 06, 2022: Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2023 Results: November 7, 2022 201

6.90 Oct 05, 2022: DiaSorin Gets $31M BARDA Funding for Point-of-Care Instrument 202

6.91 Oct 04, 2022: Haemonetics appoints Roy Galvin as President, Global Plasma and Blood Center 202

6.92 Sep 30, 2022: Theradiag: Appointment of an Independent Expert 202

6.93 Sep 26, 2022: Leuko raises Series A funds to validate WBC monitoring solution 203

6.94 Sep 19, 2022: Theradiag Announces Its Results for the First Half of 2022: Breaking-Even and Confirming Its Ability to Be Structurally Profitable From Early 2023 204

6.95 Sep 15, 2022: New article brings forward support for home dialysis in connection with comorbidities 205

6.96 Sep 14, 2022: Horiba announces Review of First Half of 2022 206

6.97 Sep 07, 2022: Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference 206

6.98 Sep 07, 2022: Medtronic to appear at September investor conferences 207

6.99 Sep 06, 2022: Labcorp to Speak at the Baird 2022 Global Healthcare Conference 207

6.100 Sep 01, 2022: Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis 207

6.101 Sep 01, 2022: Abcam to participate in the Morgan Stanley 20th Annual Global Healthcare Conference 208

6.102 Sep 01, 2022: Angle PLC Notice of Interim Results and Webcast 208

6.103 Aug 24, 2022: BD to Present at the Wells Fargo 2022 Healthcare Conference 208

6.104 Aug 23, 2022: Medtronic reports first quarter fiscal 2023 financial results 208

6.105 Aug 23, 2022: Medtronic Announces Quarterly Earnings Results 211

6.106 Aug 23, 2022: Novartis set to eliminate many leadership positions as part of 1,400 layoffs in Switzerland 214

6.107 Aug 12, 2022: Horiba announce Summary of Consolidated Financial Statements for the Six Months Ended June 30, 2022 214

6.108 Aug 11, 2022: Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update 215

6.109 Aug 10, 2022: Haemonetics Reports First Quarter Fiscal 2023 Results; Updates Fiscal 2023 Guidance; Announces New $300 Million Share Repurchase Authorization 217

6.110 Aug 08, 2022: Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results 219

6.111 Aug 04, 2022: Kimball Electronics announces results for Q4 and fiscal year ended June 30, 2022 220

6.112 Aug 01, 2022: GC Biopharma Reports Q2 2022 Results 221

6.113 Aug 01, 2022: Quanterix’ Second Quarter 2022 Earnings Conference Call 221

6.114 Jul 28, 2022: Labcorp Announces 2022 Second Quarter Results 222

6.115 Jul 28, 2022: Bio-rad Reports Second-quarter 2022 Financial Results 225

6.116 Jul 28, 2022: GC Care to start hiring experienced workers in the third quarter of 2022Platform Expert Recruitment 229

6.117 Jul 28, 2022: Grifols Report EUR 2,810.1 million revenues in first half of 2022 230

6.118 Jul 25, 2022: Beckman Coulter partners with Mass General and BARDA to identify severe pediatric infections in emergency departments 232

6.119 Jul 24, 2022: Central Trust Buys 136 Shares of Novartis AG 233

6.120 Jul 21, 2022: Roche: Appointed Thomas Schinecker as New CEO Effective March 15, 2023 233

6.121 Jul 20, 2022: Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance 233

6.122 Jul 18, 2022: Theradiag Reports Revenue of €6.3 Million for the First Half of 2022, Up

14.3% 234

6.123 Jul 18, 2022: Bio-Rad to Report Second Quarter 2022 Financial Results on Thursday, July 28, 2022 235

6.124 Jul 13, 2022: Anaveon appoints Dr Gary Phillips as Chief Business Officer 235

6.125 Jul 01, 2022: Hemcheck signed distribution agreement for the Spanish market 236

6.126 Jul 01, 2022: Novartis Leaning Toward Spinoff of $25 Billion Generics Arm 236

6.127 Jun 30, 2022: Novartis to cut up to 8,000 jobs globally 236

6.128 Jun 27, 2022: Medtronic Board appoints Lidia Fonseca as a new director 236

6.129 Jun 24, 2022: Quotient Ltd Provides Fourth Quarter Fiscal 2022 Results and Business Update 237

6.130 Jun 24, 2022: Quotient Provides Fourth Quarter Fiscal 2022 Results and Business Update 239

6.131 Jun 21, 2022: Quotient Reschedules Fourth Quarter and Full Year 2022 Financial Results Announcement to Friday, June 24th and Provides a Preview of Financials 239

6.132 Jun 17, 2022: Quotient to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on June 22nd 240

6.133 Jun 09, 2022: EKF Diagnostics Holdings : Launch of EKF Link 240

6.134 Jun 08, 2022: PixCell Medical Names Mark Erez as Chief Financial Officer 241

6.135 Jun 08, 2022: Integrated Diagnostics Holdings 1st Quarter 2022 Results 242

6.136 Jun 07, 2022: BD Names Simon Campion as Medical Segment President 246

6.137 Jun 02, 2022: BD to Present at Goldman Sachs 43rd Annual Global Healthcare Conference 246

7 Appendix 247

7.1 Methodology 247

7.2 About GlobalData 250

7.3 Contact Us 250

7.4 Disclaimer 250

Table

Hematology – Pipeline Products by Stage of Development 17

Hematology – Pipeline Products by Segment 18

Hematology – Pipeline Products by Territory 19

Hematology – Pipeline Products by Regulatory Path 20

Hematology – Pipeline Products by Estimated Approval Date 21

Hematology – Ongoing Clinical Trials 22

Hematology Companies – Pipeline Products by Stage of Development 23

Hematology – Pipeline Products by Stage of Development 26

AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 29

ABO Diagnostic Test – Product Status 29

ABO Diagnostic Test – Product Description 29

Aggredyne Inc Pipeline Products & Ongoing Clinical Trials Overview 30

AggreGuide A-600 – Product Status 30

AggreGuide A-600 – Product Description 30

Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 31

ALBAclone Anti-C beta Reagent – Product Status 31

ALBAclone Anti-C beta Reagent – Product Description 31

ALBAclone Anti-e beta Reagent – Product Status 32

ALBAclone Anti-e beta Reagent – Product Description 32

ALBAclone Anti-H Reagent – Product Status 32

ALBAclone Anti-H Reagent – Product Description 32

ALBAcyte O Adult i Cell Reagent – Product Status 33

ALBAcyte O Adult i Cell Reagent – Product Description 33

ALBAcyte O RhD VI Reagent Cells – Product Status 33

ALBAcyte O RhD VI Reagent Cells – Product Description 33

Amity University Pipeline Products & Ongoing Clinical Trials Overview 34

Blood Group Testing Kit – Product Status 34

Blood Group Testing Kit – Product Description 34

Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 35

Coagulyzer APTT Calibrator – Product Status 35

Coagulyzer APTT Calibrator – Product Description 35

Coagulyzer Calcium Chloride Calibrator – Product Status 36

Coagulyzer Calcium Chloride Calibrator – Product Description 36

Coagulyzer Calcium Chloride Control – Product Status 36

Coagulyzer Calcium Chloride Control – Product Description 36

Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 37

HemoPlex Kell Genotyping Kit – Product Status 37

HemoPlex Kell Genotyping Kit – Product Description 37

HemoPlex Kidd And Duffy Genotyping Kit – Product Status 38

HemoPlex Kidd And Duffy Genotyping Kit – Product Description 38

HemoPlex MNS Genotyping Kit – Product Status 38

HemoPlex MNS Genotyping Kit – Product Description 39

HemoPlex Multi Blood Group Genotyping Kit – Product Status 39

HemoPlex Multi Blood Group Genotyping Kit – Product Description 39

HemoPlex RHCE Screening Kit – Product Status 40

HemoPlex RHCE Screening Kit – Product Description 40

HemoPlex RHCE Variant Genotyping Kit – Product Status 40

HemoPlex RHCE Variant Genotyping Kit – Product Description 41

HemoPlex RHD And CE Genotyping Kit – Product Status 41

HemoPlex RHD And CE Genotyping Kit – Product Description 41

HemoPlex RHD Variant Genotyping Kit – Product Status 42

HemoPlex RHD Variant Genotyping Kit – Product Description 42

ThromboPlex HPA Screening Kit – Product Status 42

ThromboPlex HPA Screening Kit – Product Description 43

Blaze Medical Devices, LLC Pipeline Products & Ongoing Clinical Trials Overview 44

Fragility Test – Product Status 44

Fragility Test – Product Description 44

Calviri Inc Pipeline Products & Ongoing Clinical Trials Overview 45

Blood Screening Immunosignaturing – Product Status 45

Blood Screening Immunosignaturing – Product Description 45

Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 46

Thrombogent – Product Status 46

Thrombogent – Product Description 46

Children’s Hospital of Philadelphia Pipeline Products & Ongoing Clinical Trials Overview 47

Rh Antigen Screening Reagent – Product Status 47

Rh Antigen Screening Reagent – Product Description 47

CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview 48

FACSGuard – Product Status 48

FACSGuard – Product Description 48

CW Optics Inc Pipeline Products & Ongoing Clinical Trials Overview 49

Optical Sensor – Product Status 49

Optical Sensor – Product Description 49

Diagnostica Stago Inc Pipeline Products & Ongoing Clinical Trials Overview 50

STA Compact Max – Apixaban Calibrators And Controls – Product Status 50

STA Compact Max – Apixaban Calibrators And Controls – Product Description 51

STA Compact Max – Dabigatran Calibrator And Control – Product Status 51

STA Compact Max – Dabigatran Calibrator And Control – Product Description 51

STA Compact Max – Edoxaban Calibrator And Control – Product Status 52

STA Compact Max – Edoxaban Calibrator And Control – Product Description 52

STA-R Evolution Expert – Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa – Product Status 52

STA-R Evolution Expert – Rivaroxaban and Apixaban Calibrators And Controls For Anti-Xa – Product Description 53

STA-R Max – Apixaban Calibrators And Controls – Product Status 53

STA-R Max – Apixaban Calibrators And Controls – Product Description 53

STA-R Max – Dabigatran Calibrator And Control – Product Status 54

STA-R Max – Dabigatran Calibrator And Control – Product Description 54

STA-R Max – Edoxaban Calibrator And Control – Product Status 54

STA-R Max – Edoxaban Calibrator And Control – Product Description 55

DNA Medicine Institute (DMI) Inc Pipeline Products & Ongoing Clinical Trials Overview 56

Stat Palm-Sized Blood Counter – Product Status 56

Stat Palm-Sized Blood Counter – Product Description 56

ELITechGroup Inc Pipeline Products & Ongoing Clinical Trials Overview 57

ELITe Ingenius Coagulation Factors Reagent – Product Status 57

ELITe Ingenius Coagulation Factors Reagent – Product Description 57

Embryyo Technologies Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 58

Diagnostic Device – Bleeding Disorder – Product Status 58

Diagnostic Device – Bleeding Disorder – Product Description 58

Point Of Care Device – Platelet Function – Product Status 59

Point Of Care Device – Platelet Function – Product Description 59

Endpoint Health Inc Pipeline Products & Ongoing Clinical Trials Overview 60

Companion Diagnostic Test – Antithrombin III – Product Status 60

Companion Diagnostic Test – Antithrombin III – Product Description 60

Genome Diagnostics B.V. Pipeline Products & Ongoing Clinical Trials Overview 61

Blood Group Sequencing Assay – Product Status 61

Blood Group Sequencing Assay – Product Description 61

NGSgo-AmpX v2 Prototype Assay – Product Status 62

NGSgo-AmpX v2 Prototype Assay – Product Description 62

Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 63

Extended Blood Typing Reagent – Product Status 63

Extended Blood Typing Reagent – Product Description 63

IH Blood Genotyping (D) Kit – Product Status 64

IH Blood Genotyping (D) Kit – Product Description 64

Haemokinesis Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 65

Blood Incubator – Product Status 65

Blood Incubator – Product Description 65

Haemonetics Corp Pipeline Products & Ongoing Clinical Trials Overview 66

Four-Channel Platelet Mapping Cartridge – Product Status 66

Four-Channel Platelet Mapping Cartridge – Product Description 66

In Vitro Diagnostic Solutions Inc Pipeline Products & Ongoing Clinical Trials Overview 67

Single Analyte Detection Test – Product Status 67

Single Analyte Detection Test – Product Description 67

Indian Institute of Technology Bombay Pipeline Products & Ongoing Clinical Trials Overview 68

Hb Quantifier – Product Status 68

Hb Quantifier – Product Description 68

Instrumentation Laboratory Co Pipeline Products & Ongoing Clinical Trials Overview 69

HemosIL Apixaban Testing Assay – Product Status 69

HemosIL Apixaban Testing Assay – Product Description 69

King’s College London Pipeline Products & Ongoing Clinical Trials Overview 70

Non-Transferrin-Bound Iron Assay – Product Status 70

Non-Transferrin-Bound Iron Assay – Product Description 70

Laboratorios Alpha San Ignacio Pharma S.L. Pipeline Products & Ongoing Clinical Trials Overview 71

Double Trust – Product Status 71

Double Trust – Product Description 71

LeukoLab Pipeline Products & Ongoing Clinical Trials Overview 72

PointCheck – Product Status 72

PointCheck – Product Description 72

LeukoLab – Ongoing Clinical Trials Overview 73

PointCheck – A Study to Evaluate the Usability, Adherence and Diagnostic Performance of a Novel System to Non-Invasively Detect Severe Neutropenia 74

PointCheck – PC001 – Study to Evaluate the Usability of PointCheck, a Novel Optical Technology for Screening Non-invasively Severe Neutropenia 74

PointCheck – Study to Evaluate the Usability of PointCheck, a Novel Optical Technology for Screening Non-invasively Severe Neutropenia 74

Massachusetts General Hospital Pipeline Products & Ongoing Clinical Trials Overview 75

iCoagLab – Product Status 75

iCoagLab – Product Description 75

Medical University of Vienna Pipeline Products & Ongoing Clinical Trials Overview 76

Prediction Test – Venous Thromboembolism – Product Status 76

Prediction Test – Venous Thromboembolism – Product Description 76

MedPrime Technologies Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 77

Automated Blood Typing Device – Product Status 77

Automated Blood Typing Device – Product Description 77

Mylab Discovery Solutions Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 78

Compact x System – Molecular Blood Grouping Test – Product Status 78

Compact x System – Molecular Blood Grouping Test – Product Description 78

Nanospot.ai Inc Pipeline Products & Ongoing Clinical Trials Overview 79

Blood Typing Antibody Test – Product Status 79

Blood Typing Antibody Test – Product Description 79

Neuron Biopharma SA Pipeline Products & Ongoing Clinical Trials Overview 80

Diagnostic Blood Test – Athletes – Product Status 80

Diagnostic Blood Test – Athletes – Product Description 80

Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 81

Diagnostic Kit – Heavy Metal Poisoning – Product Status 81

Diagnostic Kit – Heavy Metal Poisoning – Product Description 81

Ortho Clinical Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 82

ORTHO AutoVue – Rare Sera Assay – Product Status 82

ORTHO AutoVue – Rare Sera Assay – Product Description 82

ORTHO BioVue – Rare Sera Assay – Product Status 83

ORTHO BioVue – Rare Sera Assay – Product Description 83

PixCell Medical Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 84

HemoScreen – Home Use – Product Status 84

HemoScreen – Home Use – Product Description 84

HemoScreen Platelets Aggregation Test Cartridge – Product Status 85

HemoScreen Platelets Aggregation Test Cartridge – Product Description 85

Plakdx LLC Pipeline Products & Ongoing Clinical Trials Overview 86

MICELI Aggregometer – Product Status 86

MICELI Aggregometer – Product Description 86

Pro Test Diagnostics AB Pipeline Products & Ongoing Clinical Trials Overview 87

ABT Test – Product Status 87

ABT Test – Product Description 87

Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 88

ALBAcyte Antibody Identification Cells – B – Product Status 88

ALBAcyte Antibody Identification Cells – B – Product Description 89

ALBAcyte Rh – Screening Cells – Product Status 89

ALBAcyte Rh – Screening Cells – Product Description 89

ALBAcyte Screening Cells (2 cell) – Product Status 89

ALBAcyte Screening Cells (2 cell) – Product Description 90

Complement Coated Cells – Product Status 90

Complement Coated Cells – Product Description 90

Eluate Kit – Product Status 90

Eluate Kit – Product Description 91

Expanded IH Microarray – Product Status 91

Expanded IH Microarray – Product Description 91

IH Microarray Patient – Product Status 91

IH Microarray Patient – Product Description 92

MosaiQ Expanded IH Microarray – Product Status 92

MosaiQ Expanded IH Microarray – Product Description 92

Polyagglutionation Kit – Product Status 93

Polyagglutionation Kit – Product Description 93

Sensitivity Kit Anti-S, K, e, C – Product Status 93

Sensitivity Kit Anti-S, K, e, C – Product Description 93

WARM Antibody Removal Reagent – Product Status 94

WARM Antibody Removal Reagent – Product Description 94

Rapidx, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 95

RapiDx Sampling System – Product Status 95

RapiDx Sampling System – Product Description 95

Redbud Labs Inc Pipeline Products & Ongoing Clinical Trials Overview 96

Point-Of-Care Diagnostic Device – Transfusion Therapy – Product Status 96

Point-Of-Care Diagnostic Device – Transfusion Therapy – Product Description 96

Sebia SA Pipeline Products & Ongoing Clinical Trials Overview 97

Capillarys 3 Tera – Hemoglobin Adult Guthrie Assay – Product Status 97

Capillarys 3 Tera – Hemoglobin Adult Guthrie Assay – Product Description 98

Capillarys 3 Tera – Hemoglobin Neonatal Cord Blood Assay – Product Status 98

Capillarys 3 Tera – Hemoglobin Neonatal Cord Blood Assay – Product Description 98

Capillarys 3 Tera – Hemoglobin Neonatal Guthrie Assay – Product Status 99

Capillarys 3 Tera – Hemoglobin Neonatal Guthrie Assay – Product Description 99

Capillarys 3 Tera – Hemoglobin Whole Blood Assay – Product Status 99

Capillarys 3 Tera – Hemoglobin Whole Blood Assay – Product Description 100

Diagnostic Test – Haemoglobin Diseases – Product Status 100

Diagnostic Test – Haemoglobin Diseases – Product Description 100

SiDx Inc Pipeline Products & Ongoing Clinical Trials Overview 101

Blood Group Testing Chip – Product Status 101

Blood Group Testing Chip – Product Description 101

Sigma Bio-Instrument Inc Pipeline Products & Ongoing Clinical Trials Overview 102

Automated Cell Counting System – Product Status 102

Automated Cell Counting System – Product Description 102

Stichting Lygature Pipeline Products & Ongoing Clinical Trials Overview 103

Diagnostic Assay Device – Product Status 103

Diagnostic Assay Device – Product Description 103

Streck Inc Pipeline Products & Ongoing Clinical Trials Overview 104

CD-Chex CD103 Plus – Product Status 104

CD-Chex CD103 Plus – Product Description 104

CD-Chex CD117 Plus – Product Status 105

CD-Chex CD117 Plus – Product Description 105

CD-Chex Select – Product Status 105

CD-Chex Select – Product Description 106

CD-Chex TdT Plus – Product Status 106

CD-Chex TdT Plus – Product Description 106

LBC-Chex – Product Status 107

LBC-Chex – Product Description 107

TBG Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 108

TBG Kit – Blood Safety – Product Status 108

TBG Kit – Blood Safety – Product Description 108

The University of British Columbia Pipeline Products & Ongoing Clinical Trials Overview 109

Microfluidic Device – Blood Transfusion – Product Status 109

Microfluidic Device – Blood Transfusion – Product Description 109

Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 110

Aegis – Anti-A Quantitation In Group O Platelets – Product Status 110

Aegis – Anti-A Quantitation In Group O Platelets – Product Description 110

Aegis – Antibody Screening And Identification Assay – Product Status 111

Aegis – Antibody Screening And Identification Assay – Product Description 111

Aegis – Blood Grouping Assay – Product Status 111

Aegis – Blood Grouping Assay – Product Description 112

Aegis – Crossmatch Assay – Product Status 112

Aegis – Crossmatch Assay – Product Description 112

Aegis – Feto-Maternal Hemorrhage Assay – Product Status 113

Aegis – Feto-Maternal Hemorrhage Assay – Product Description 113

Aegis – HLA/TRALI Assay – Product Status 113

Aegis – HLA/TRALI Assay – Product Description 114

Aegis – Platelet Cross-match Assay – Product Status 114

Aegis – Platelet Cross-match Assay – Product Description 114

Aegis – Residual A Quantitation Assay – Product Status 115

Aegis – Residual A Quantitation Assay – Product Description 115

Aegis – rWBC Quantitation Assay – Product Status 115

Aegis – rWBC Quantitation Assay – Product Description 116

AEGIS System – Product Status 116

AEGIS System – Product Description 116

University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 117

Rh (D) Human Blood Typing Reagent – Product Status 117

Rh (D) Human Blood Typing Reagent – Product Description 117

University of Utah Pipeline Products & Ongoing Clinical Trials Overview 118

ITEM – Viscoelastic Testing – Product Status 118

ITEM – Viscoelastic Testing – Product Description 118

Victory Square Health Inc Pipeline Products & Ongoing Clinical Trials Overview 119

Diagnostic Kit – Blood Sample Screening Test – Product Status 119

Diagnostic Kit – Blood Sample Screening Test – Product Description 119

Washington University in St Louis Pipeline Products & Ongoing Clinical Trials Overview 120

Diagnostic Assay – Thrombotic Microangiopathy – Product Status 120

Diagnostic Assay – Thrombotic Microangiopathy – Product Description 120

Glossary 249

Figures

Hematology – Pipeline Products by Stage of Development 17

Hematology – Pipeline Products by Segment 18

Hematology – Pipeline Products by Territory 19

Hematology – Pipeline Products by Regulatory Path 20

Hematology – Pipeline Products by Estimated Approval Date 21

Hematology – Ongoing Clinical Trials 22

Frequently asked questions

Hematology Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies standard reports
Currency USD
$4,000

Can be used by individual purchaser only

Most Popular
$8,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Hematology Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Hematology reports
Medical Devices
New
Adult Feeding Tubes and Formula Market Size by Segments, Share,…
$7,500 | October 2026
Medical Devices
New
Neurovascular Thrombectomy Devices Market Size by Segments, Share, Regulatory, Reimbursement,…
$7,500 | October 2026
Medical Devices
New
Body Contouring Devices Market Size by Segments, Share, Regulatory, Reimbursement,…
$7,500 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hematology Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies in real time.

  • Access a live Hematology Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more